In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication

Journal of Virology

Volumn 81, Issue 7, 2007, Pages 3068-3076

  Heipertz Jr , Richard A ^a   Miller, Thomas G ^a   Kelley, Colleen M ^a   Delaney IV, William E ^b,c   Locarnini, Stephen A ^b   Isom, Harriet C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; ISOLEUCINE; LAMIVUDINE; METHIONINE; NUCLEIC ACID; VIRUS DNA;

ARTICLE; BACULOVIRUS; CELL STRAIN HEPG2; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; BACULOVIRIDAE; CELL LINE; CELL NUCLEUS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; SPODOPTERA; TRANSCRIPTION, GENETIC; VIRAL CORE PROTEINS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 33947414387     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02341-06     Document Type: Article

References (55)

1. Abdelhamed, A. M., C. M. Kelley, T. G. Miller, P. A. Furman, E. E. Cable, and H. C. Isom. 2003. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob. Agents Chemother. 47:324-336.
2. Abdelhamed, A. M., C. M. Kelley, T. G. Miller, P. A. Furman, and H. C. Isom. 2002. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J. Virol. 76:8148-8160.
3. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
4. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
5. Baumert, T. F., A. Marrone, J. Vergalla, and T. J. Liang. 1998. Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression. J. Virol. 72:6785-6795.
6. Boyce, F. M., and N. L. Bucher. 1996. Baculovirus-mediated gene transfer into mammalian cells. Proc. Natl. Acad. Sci. USA 93:2348-2352.
7. Brunetto, M. R., M. M. Giarin, F. Oliveri, E. Chiaberge, M. Baldi, A Alfarano, A. Serra, G. Saracco, G. Verme, and H. Will. 1991. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis B. Proc. Natl. Acad. Sci. USA 88:4186-4190.
8. Brunetto, M. R., M. Stemler, F. Schodel, H. Will, A. Ottobrelli, M. Rizzetto, G. Verme, and F. Bonino. 1989. Identification of HBV mutants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis. Int. J. Gastroenterol. 2:151-154.
9. Carman, W. F., M. R. Jacyna, S. Hadziyannis, P. Karayiannis, M. J. McGarvey, A. Makris, and H. C. Thomas. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii:588-591.
10. Chen, R. Y., R. Edwards, T. Shaw, D. Colledge, W. E. I. Delaney, H. Isom, S. Bowden, P. Desmond, and S. A. Locarnini. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
11. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
12. Chun, Y. K., J. Y. Kim, H. J. Woo, S. M. Oh, I. Kang, J. Ha, and S. S. Kim. 2000. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 32:1154-1162.
13. Delaney, W. E. I., and H. C. Isom. 1998. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28:1134-1146.
14. Delaney, W. E. I., T. G. Miller, and H. C. Isom. 1999. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob. Agents Chemother. 43:2017-2026.
15. de Man, R. A., P. Honkoop, H. L. Janssen, and S. W. Schalm. 1999. Chronic hepatitis-B-virus infections: new options for antiviral therapy. Ned. Tijdschr. Geneeskd. 143:1857-1861.
16. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. Hann, Z. Goodman, L. Crowther, L. D. Condreay, M. Woessner, M. Rubin, and N. A Brown. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
17. Fu, L., and Y. C. Cheng. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55:1567-1572.
18. Gaillard, R. K., J. Barnard, V. Lopez, P. Hodges, E. Bourne, L. Johnson, M. I. Allen, P. Condreay, W. H. Miller, and L. D. Condreay. 2002. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob. Agents Chemother. 46:1005-1013.
19. Ganem, D., and H. E. Varmus. 1987. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56:651-693.
20. Hadziyannis, S. J., and D. Vassilopoulos. 2001. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624.
21. Honkoop, P., H. G. Niesters, R. A. de Man, A. D. Osterhaus, and S. W. Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26:1393-1395.
22. Hoofnagle, J. H., and A M. di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
23. Jarvis, B., and D. Faulds. 1999. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 58:101-141.
24. Knowles, B. B., C. C. Howe, and D. P. Aden. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499.
25. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
26. Li, J., V. E. Buckwold, M. W. Hon, and J. H. Ou. 1999. Mechanism of suppression of hepatitis B virus precote RNA transcription by a frequent double mutation. J. Virol. 73:1239-1244.
27. Liaw, Y. F., R. N. Chien, C. T. Yeh, S. L. Tsai, and C. M. Chu. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
28. Lok, A. S., U. Akarca, and S. Greene. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc. Natl. Acad. Sci. USA 91:4077-4081.
29. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
30. Milich, D. R., M. K. Chen, J. L. Hughes, and J. E. Jones. 1998. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 160:2013-2021.
31. Milich, D. R., J. E. Jones, J. L. Hughes, J. Price, A K. Raney, and A McLachlan. 1990. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA 87:6599-6603.
32. Naoumov, N. V., R. Schneider, T. Grotzinger, M. C. Jung, S. Miska, G. R. Pape, and H. Will. 1992. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 102:538-543.
33. Niederau, C., T. Heintges, S. Lange, G. Goldmann, C. M. Niederau, L. Mohr, and D. Haussinger. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334:1422-1427.
34. Okamoto, H., F. Tsuda, Y. Akahane, Y. Sugai, M. Yoshiba, K. Moriyama, T. Tanaka, Y. Miyakawa, and M. Mayumi. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 68:8102-8110.
35. Ono-Nita, S. K., N. Kato, Y. Shiratori, K. H. Lan, H. Yoshida, F. J. Carrilho, and M. Omata. 1999. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J. Clin. Investig. 103:1635-1640.
36. Ono-Nita, S. K., N. Kato, Y. Shiratori, T. Masaki, K. H. Lan, F. J. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
37. O'Reilly, D. R. 1997. Use of baculovirus expression vectors. Methods Mol. Biol. 62:235-246.
38. Ou, J. H., O. Laub, and W. J. Rutter. 1986. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl. Acad. Sci. USA 83:1578-1582.
39. Pallier, C., L. Castera, A. Soulier, C. Hezode, P. Nordmann, D. Dhumeaux, and J. M. Pawlotsky. 2006. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 80:643-653.
40. Perrillo, R., H. W. Hann, D. Mutimer, B. Willems, N. Leung, W. M. Lee, A. Moorat, S. Gardner, M. Woessner, E. Bourne, C. L. Brosgart, and E. Schiff. 2004. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126:81-90.
41. Peters, M. G., G. Singer, T. Howard, S. Jacobsmeyer, X. Xiong, C. S. Gibbs, P. Lamy, and A. Murray. 1999. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68:1912-1914.
42. Raimondo, G., E. Tanzi, S. Brancatelli, S. Campo, M. A. Sardo, G. Rodino, M. Pernice, and A. R. Zanetti. 1993. Is the course of perinatal hepatitis B virus infection influenced by genetic heterogeneity of the virus? J. Med. Virol. 40:87-90.
43. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Analysis and cloning of eukaryotic genomic DNA, p. 9.1-9.62. In Molecular cloning. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
44. Santantonio, T., M. C. Jung, S. Miska, G. Pastore, G. R. Pape, and H. Will. 1991. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology 183:840-844.
45. Santantonio, T., M. Mazzola, T. Iacovazzi, A. Miglietta, A. Guastadisegni, and G. Pastore. 2000. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32:300-306.
46. Schiff, E. R., C. L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, M. Colombo, H. L. Tillmann, D. Samuel, S. Zeuzem, L. Lilly, M. Rendina, J. P. Villeneuve, N. Lama, C. James, M. S. Wulfsohn, H. Namini, C. Westland, S. Xiong, G. S. Choy, S. Van Doren, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419-1427.
47. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
48. Tine, F., A. Liberati, A. Craxi, P. Almasio, and L. Pagliaro. 1993. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J. Hepatol. 18:154-162.
49. Tong, S. P., J. S. Li, L. Vitritski, and C. Trepo. 1992. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology 191:237-245.
50. Ulrich, P. P., R. A. Bhat, I. Kelly, M. R. Brunetto, F. Bonino, and G. N. Vyas. 1990. A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease. J. Med. Virol. 32:109-118.
51. Uy, A., V. Bruss, W. H. Gerlich, H. G. Kochel, and R. Thomssen. 1986. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein. Virology 155:89-96.
52. Wei, Y., J. E. Tavis, and D. Ganem. 1996. Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses. J. Virol. 70:6455-6458.
53. Weimer, T., J. Salfeld, and H. Will. 1987. Expression of the hepatitis B virus core gene in vitro and in vivo. J. Virol. 61:3109-3113.
54. Wong, D. K., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323.
55. Yuh, C. H., Y. L. Chang, and L. P. Ting. 1992. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J. Virol. 66:4073-4084.